Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study

被引：0

作者：

Even, C. ^{[1
]}

Bernard-Tessier, A. ^{[2
]}

Texier, M. ^{[3
]}

Said, O. Ben ^{[4
]}

Iacob, M. ^{[5
]}

Daste, A. ^{[6
]}

Fayette, J. ^{[7
]}

Zanetta, S. ^{[8
]}

Lefebvre, G. ^{[9
]}

Vinches, M. ^{[10
]}

Johnson, A. C. ^{[11
]}

Le Moal, L. Bozec ^{[12
]}

Saada, E. B. ^{[13
]}

Jallut, I. ^{[14
]}

Garic, F. ^{[15
]}

Monard, L. ^{[16
]}

Bourhis, J. ^{[17
]}

Guigay, J. ^{[18
]}

Auperin, A. ^{[19
]}

Ammari, S. ^{[20
]}

机构：

[1] Inst Gustave Roussy, Head & Neck Oncol Dept, Villejuif, France

[2] Inst Gustave Roussy, Oncol Dept, Villejuif, France

[3] Inst Gustave Roussy, Biostat & Epidemiol, Villejuif, France

[4] Gustave Roussy, Radiol, Canc Campus, Villejuif, France

[5] IRO Reg Inst Oncol, Med Oncol Dept, Villejuif, France

[6] CHU Bordeaux, Med Oncol Dept, Hop St Andre, Bordeaux, France

[7] Ctr Leon Berard, Med Oncol Dept, Lyon, France

[8] Ctr Georges Francois Leclerc Dijon, Med Oncol Dept, Dijon, France

[9] Ctr Oscar Lambret, Med Oncol Dept, Lille, France

[10] ICM Inst Canc Montpellier, Med Oncol Dept, Montpellier, France

[11] Ctr Francois Baclesse, Med Oncol Dept, Caen, France

[12] Hop Rene Huguenin, Inst Curie, Med Oncol Dept, St Cloud, France

[13] Ctr Anticancer Antoine Lacassagne, Med Oncol, Nice, France

[14] Unicancer, R&D, Paris, France

[15] Unicancer, Paris, France

[16] Unicancer, UCGI R&D, Paris, France

[17] CHU Vaudois, Radiat Oncol Dept, UNIL CHUV, Lausanne, Switzerland

[18] Ctr Anticancer Antoine Lacassagne, Med Oncol Dept, Nice, France

[19] Gustave Roussy, Biostat & Epidemiol, Canc Campus, Villejuif, France

[20] Gustave Roussy, Med Oncol Dept, Canc Campus, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.799

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

675P

引用

页码：S851 / S851

页数：1

共 50 条

[31] Genomic characteristics and immunotherapy outcomes in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Park, J. C.
Cortes, M. Useche
Durbeck, J.
Clark, J. R.
Zhao, Y.
Saladi, S. V.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S856 - S856
[32] A phase II study of ispinesib in patients (PTS) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC)
Tang, Patricia
Siu, Lillian L.
Chen, Eric X.
Hotte, Sebastien J.
Chia, Stephen
Schwarz, James K.
Colevas, A. Dimitrios
Johnson, Caitlin
Pond, Greg R.
Winquist, Eric
ANNALS OF ONCOLOGY, 2006, 17 : 186 - 186
[33] Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts)
Stokes, M.
Wang, R.
Wildsmith, S.
Secrier, M.
Angell, H. K.
Barker, C.
Walker, J.
Scorer, P.
Rebelatto, M. C.
Shire, N.
ANNALS OF ONCOLOGY, 2017, 28
[34] Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1)
Cohen, E.
Licitra, L.
Burtness, B.
Fayette, J.
Gauler, T.
Clement, P. M.
Grau, J. J.
del Campo, J. M.
Mailliez, A.
Haddad, R. I.
Vermorken, J. B.
Tahara, M.
Guigay, J.
Geoffrois, L.
Merlano, M. C.
Cong, X. J.
Gibson, N.
Solca, F.
Ehrnrooth, E.
Machiels, J. P. H.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 868 - 869
[35] TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC
Even, C.
Daste, A.
Saada-Bouzid, E.
Fayette, J.
Kaminsky-Forrett, M-C.
Zanetta, S.
Prevost, A.
Lefebvre, G.
Borel, C.
Cupissol, D.
Huguet, F.
Delord, J-P.
Rotllan, N. Baste
Delaye, J.
Jallut, I.
Vintonenko, N.
Bourhis, J.
Guigay, J.
Texier, M.
Auperin, A.
ANNALS OF ONCOLOGY, 2018, 29 : 380 - 380
[36] The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort
Lynggaard, Charlotte Duch
Therkildsen, Marianne Hamilton
Kristensen, Claus Andrup
Specht, Lena
ACTA ONCOLOGICA, 2015, 54 (07) : 1071 - U151
[37] Survival outcomes of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with platinum-based chemotherapy plus paclitaxel after anti-PD-1 monotherapy.
Burkitt, Kyunghee
Fu, Pingfu
Margevicius, Seunghee
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[38] Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
Economopoulou, Panagiota
Gavrielatou, Niki
Papaxoinis, George
Kotsantis, Ioannis
Pantazopoulos, Anastasios
Anastasiou, Maria
Kavourakis, George
Gkolfinopoulos, Stavros
Psyrri, Amanda
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[39] SAR445256 (KY1044) in combination with atezolizumab in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Patel, M.
Ascierto, P. A.
Thistlethwaite, F.
Adkins, D. R.
Villaflor, V. Meucci
Galizia, D.
Calabro, L.
Di Maio, M.
D'Ambrosio, C.
Bertolini, A.
Damato, A.
Deantonio, C.
Yang, Y.
Kurup, D.
Abbadessa, G.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S864 - S865
[40] A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
Rischin, Danny
Boyer, Michael J.
Brzezniak, Christina E.
Colevas, A. Dimitrios
Doebele, Robert Charles
Gilbert, Jill
Gitlitz, Barbara
Khan, Saad A.
Mehra, Ranee
Seiwert, Tanguy Y.
Kroll, Stew
Pearce, Tillman E.
Liu, Stephen V.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →